Response to first line chemotherapy regimen is associated with efficacy of nivolumab in non-small-cell lung cancer
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Response to first line chemotherapy regimen is associated with efficacy of nivolumab in non-small-cell lung cancer
Authors
Keywords
-
Journal
OncoImmunology
Volume 6, Issue 9, Pages e1339856
Publisher
Informa UK Limited
Online
2017-06-16
DOI
10.1080/2162402x.2017.1339856
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Autophagy, Inflammation, and Immunity: A Troika Governing Cancer and Its Treatment
- (2016) Zhenyu Zhong et al. CELL
- Immunogenic versus tolerogenic phagocytosis during anticancer therapy: mechanisms and clinical translation
- (2016) A D Garg et al. CELL DEATH AND DIFFERENTIATION
- Genomic Approaches to Understanding Response and Resistance to Immunotherapy
- (2016) D. A. Braun et al. CLINICAL CANCER RESEARCH
- PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis
- (2016) Sara Gandini et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- RECIST 1.1—Update and clarification: From the RECIST committee
- (2016) Lawrence H. Schwartz et al. EUROPEAN JOURNAL OF CANCER
- Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
- (2016) Christina Pfirschke et al. IMMUNITY
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- (2016) Louis Fehrenbacher et al. LANCET
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non–small cell lung cancer
- (2016) Kazuhiko Shien et al. LUNG CANCER
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
- (2016) N. McGranahan et al. SCIENCE
- The effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis: some chemotherapeutical drugs may finally work through immune response
- (2016) Min Luo et al. Oncotarget
- PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?
- (2016) Claud Grigg et al. Journal for ImmunoTherapy of Cancer
- Global cancer statistics, 2012
- (2015) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents
- (2015) Lorenzo Galluzzi et al. CANCER CELL
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art?
- (2015) Keith M. Kerr et al. Journal of Thoracic Oncology
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
- (2015) E. M. Van Allen et al. SCIENCE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer
- (2014) M. Aglietta et al. ANNALS OF ONCOLOGY
- B7-H1/PD-1 Blockade Therapy in Non–Small Cell Lung Cancer
- (2014) Scott Gettinger et al. CANCER JOURNAL
- Molecular Pathways: The Immunogenic Effects of Platinum-Based Chemotherapeutics
- (2014) S. V. Hato et al. CLINICAL CANCER RESEARCH
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- Two is better than one: Complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses
- (2014) Shashi Gujar et al. OncoImmunology
- Innate and adaptive immune cells in the tumor microenvironment
- (2013) Thomas F Gajewski et al. NATURE IMMUNOLOGY
- Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth
- (2012) Mélanie Bruchard et al. NATURE MEDICINE
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Natural Innate and Adaptive Immunity to Cancer
- (2011) Matthew D. Vesely et al. Annual Review of Immunology
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- 5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell-Dependent Antitumor Immunity
- (2010) J. Vincent et al. CANCER RESEARCH
- Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: A prognostic score from individual data of nine randomised trials
- (2010) Massimo Di Maio et al. EUROPEAN JOURNAL OF CANCER
- Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress
- (2010) I Martins et al. ONCOGENE
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
- (2008) Giorgio Vittorio Scagliotti et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search